House of Lords Business
Show full summary

Lord Balfe to ask Her Majesty's Government what assessment they have made of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee's recommendation to revoke the marketing authorisation of ulipristal acetate as a treatment for uterine fibroids; and whether they intend to implement the same revocation in the UK.  HL8363

Question HL8363: tabled on 22 September 2020 and due for answer by 6 October 2020

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Balfe to ask Her Majesty's Government what assessment they have made of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee's recommendation to revoke the marketing authorisation of ulipristal acetate as a treatment for uterine fibroids; and whether they intend to implement the same revocation in the UK.  HL8363
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Balfe
Conservative
Life peer